|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||150 kg/mol|
Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD70 designed for the treatment of cancer. It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F (MMAF), a cytotoxic agent.
This drug was developed by Seattle Genetics, Inc. The drug completed phase I clinical trials for renal cell carcinoma, but development was discontinued in 2013. No reason was given but SG plan to start clinical trials of SGN-CD70A in 2014.
- Statement On A Nonproprietary Name Adopted By The USAN Council: Vorsetuzumab Mafodotin, American Medical Association.
- Clinical trials for SGN-75 "Clinicaltrials.gov"
- Seattle Genetics Third Quarter 2013 Financial Report
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|